Development of [11C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status

Clinical Cancer Research

Volumn 19, Issue 1, 2013, Pages 183-193

  Bahce, Idris ^a   Smit, Egbert F ^a   Lubberink, Mark ^a,b   Van Der Veldt, Astrid A M ^a   Yaqub, Maqsood ^a   Windhorst, Albert D ^a   Schuit, Robert C ^a   Thunnissen, Erik ^a   Heideman, Daniëlle A M ^a   Postmus, Pieter E ^a   Lammertsma, Adriaan A ^a   Hendrikse, N Harry ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERLOTINIB C 11; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG UPTAKE; DRUG WITHDRAWAL; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MUTATIONAL ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TEST RETEST RELIABILITY; TRANSPORT KINETICS; TUMOR BLOOD FLOW; UNSPECIFIED SIDE EFFECT;

ADULT; BASE SEQUENCE; CARBON RADIOISOTOPES; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84872004328     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0289     Document Type: Article

References (25)

1. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
4. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
6. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-54.
7. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-71.
8. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009;69:873-8.
9. Memon AA, Weber B, Winterdahl M, Jakobsen S, Meldgaard P, Madsen HHT, et al. PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer 2011;105:1850-5.
10. Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011;6:1287.
11. Heideman D, Thunnissen F, Doeleman M, Kramer D, Verheul H, Smit E, et al. A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Anal Cell Pathol 2009;31:329-33.
12. Kramer D, Thunnissen F, Gallegos-Ruiz M, Smit E, Postmus P, Meijer C, et al. A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Anal Cell Pathol 2009;31:161-7.
13. van der Veldt AAM, Hendrikse NH, Harms HJ, Comans EFI, Postmus PE, Smit EF, et al. Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med 2010;51:1684.
14. Boellaard R, van Lingen A, van Balen SCM, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med Mol Imaging 2001;28:81-9.
15. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metabol 1996;16:42-52.
16. Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4.
17. Akaike. A new look at the statistical model identification. IEEE Trans Autom Control 1974;19:716-23.
18. Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA. Optimization algorithms and weighting factors for analysis of dynamic PET studies. Phys Med Biol 2006;51:4217-32.
19. Ruiz MIG, Floor K, Steinberg S, Grünberg K, Thunnissen FBJM, Belien JAM, et al. Combined assessment ofEGFRpathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer 2008;100:145-52.
20. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
21. Greulich H, Chen T-H, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2:e313.
22. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metabol 1990;10:740-7.
23. Visvikis D, Francis D, Mulligan R, Costa D, Croasdale I, Luthra S, et al. Comparison of methodologies for the in vivo assessment of 18 FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 2004;31:169-78.
24. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007;67:2325-30.
25. Goldstraw P, ed. IASLC staging handbook in thoracic oncology. Orange Park (FL): Editorial Rx Press; 2009.